SGMO
Sangamo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.07
+0.00%Year over year
Reported trailing growth
- Revenue
- -45.8%
- EBITDA
- -60.9%
- EBIT
- -34.4%
- EPS
- +1.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -29.2%
- EBITDA
- -30.1%
- EBIT
- -3.9%
- Net income
- -25.5%
- EPS
- +10.2%
- Free cash flow
- -44.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026